Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
This study investigated the feasibility of targeting the free, unbound forms of prostate-specific antigen (fPSA) for in vivo imaging of prostate adenocarcinomas (PCa), as PSA is produced and secreted at abundance during every clinical stage and grade of PCa, including castration-resistant disease. W...
| المؤلفون الرئيسيون: | , , , , , , , , , , , , , |
|---|---|
| التنسيق: | Journal article |
| اللغة: | English |
| منشور في: |
2012
|
| _version_ | 1826287366089736192 |
|---|---|
| author | Evans-Axelsson, S Ulmert, D Örbom, A Peterson, P Nilsson, O Wennerberg, J Strand, J Wingårdh, K Olsson, T Hagman, Z Tolmachev, V Bjartell, A Lilja, H Strand, SE |
| author_facet | Evans-Axelsson, S Ulmert, D Örbom, A Peterson, P Nilsson, O Wennerberg, J Strand, J Wingårdh, K Olsson, T Hagman, Z Tolmachev, V Bjartell, A Lilja, H Strand, SE |
| author_sort | Evans-Axelsson, S |
| collection | OXFORD |
| description | This study investigated the feasibility of targeting the free, unbound forms of prostate-specific antigen (fPSA) for in vivo imaging of prostate adenocarcinomas (PCa), as PSA is produced and secreted at abundance during every clinical stage and grade of PCa, including castration-resistant disease. We injected (125)I-labeled monoclonal antibody PSA30 (specific for an epitope uniquely accessible on fPSA alone) intravenously in male nude mice carrying subcutaneous xenografts of LNCaP tumors (n=36). Mice were sacrificed over a time course from 4 hours to 13 days after injecting (125)I-labeled PSA30. Tissue uptake of (125)I-PSA30 at 48 and 168 hours after intravenous injection was compared with two clinically used positron emission tomography radiopharmaceuticals, (18)F-fluoro-deoxy-glucose ((18)F-FDG) or (18)F-choline, in cryosections using Digital AutoRadiography (DAR) and also compared with immunohistochemical staining of PSA and histopathology. On DAR, the areas with high (125)I-PSA30 uptake corresponded mainly to morphologically intact and PSA-producing LNCaP cells, but did not associate with the areas of high uptake of either (18)F-FDG or (18)F-choline. Biodistribution of (125)I-PSA30 measured in dissected organs ex vivo during 4 to 312 hours after intravenous injection demonstrated maximum selective tumor uptake 24-48 hours after antibody injection. Our data showed selective uptake in vivo of a monoclonal antibody highly specific for fPSA in LNCaP cells. Hence, in vivo imaging of fPSA may be feasible with putative usefulness in disseminated PCa. |
| first_indexed | 2024-03-07T01:57:35Z |
| format | Journal article |
| id | oxford-uuid:9c40dfdf-ea35-4d99-a8fb-025178b513e3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:57:35Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:9c40dfdf-ea35-4d99-a8fb-025178b513e32022-03-27T00:34:40ZTargeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9c40dfdf-ea35-4d99-a8fb-025178b513e3EnglishSymplectic Elements at Oxford2012Evans-Axelsson, SUlmert, DÖrbom, APeterson, PNilsson, OWennerberg, JStrand, JWingårdh, KOlsson, THagman, ZTolmachev, VBjartell, ALilja, HStrand, SEThis study investigated the feasibility of targeting the free, unbound forms of prostate-specific antigen (fPSA) for in vivo imaging of prostate adenocarcinomas (PCa), as PSA is produced and secreted at abundance during every clinical stage and grade of PCa, including castration-resistant disease. We injected (125)I-labeled monoclonal antibody PSA30 (specific for an epitope uniquely accessible on fPSA alone) intravenously in male nude mice carrying subcutaneous xenografts of LNCaP tumors (n=36). Mice were sacrificed over a time course from 4 hours to 13 days after injecting (125)I-labeled PSA30. Tissue uptake of (125)I-PSA30 at 48 and 168 hours after intravenous injection was compared with two clinically used positron emission tomography radiopharmaceuticals, (18)F-fluoro-deoxy-glucose ((18)F-FDG) or (18)F-choline, in cryosections using Digital AutoRadiography (DAR) and also compared with immunohistochemical staining of PSA and histopathology. On DAR, the areas with high (125)I-PSA30 uptake corresponded mainly to morphologically intact and PSA-producing LNCaP cells, but did not associate with the areas of high uptake of either (18)F-FDG or (18)F-choline. Biodistribution of (125)I-PSA30 measured in dissected organs ex vivo during 4 to 312 hours after intravenous injection demonstrated maximum selective tumor uptake 24-48 hours after antibody injection. Our data showed selective uptake in vivo of a monoclonal antibody highly specific for fPSA in LNCaP cells. Hence, in vivo imaging of fPSA may be feasible with putative usefulness in disseminated PCa. |
| spellingShingle | Evans-Axelsson, S Ulmert, D Örbom, A Peterson, P Nilsson, O Wennerberg, J Strand, J Wingårdh, K Olsson, T Hagman, Z Tolmachev, V Bjartell, A Lilja, H Strand, SE Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone. |
| title | Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone. |
| title_full | Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone. |
| title_fullStr | Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone. |
| title_full_unstemmed | Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone. |
| title_short | Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone. |
| title_sort | targeting free prostate specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate specific antigen alone |
| work_keys_str_mv | AT evansaxelssons targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone AT ulmertd targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone AT orboma targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone AT petersonp targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone AT nilssono targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone AT wennerbergj targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone AT strandj targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone AT wingardhk targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone AT olssont targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone AT hagmanz targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone AT tolmachevv targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone AT bjartella targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone AT liljah targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone AT strandse targetingfreeprostatespecificantigenforinvivoimagingofprostatecancerusingamonoclonalantibodyspecificforuniqueepitopesaccessibleonfreeprostatespecificantigenalone |